Compugen Presents MAIA-Ovarian COM701 Trial Progress; Data Due Q1 2027
CGEN•Compugen presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial evaluating COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer at the ESMO Gynaecological Cancers Congress in Copenhagen. Initial data from the COM701 trial are expected by Q1 2027, following prior signals of durable responses in platinum-resistant patients.
1. Poster Presentation at ESMO Congress
Compugen showcased a trial-in-progress poster on June 18, 2026, at the ESMO Gynaecological Cancers Congress in Copenhagen. Dr. Oladapo Yeku of Massachusetts General Hospital detailed the MAIA-ovarian adaptive platform trial (NCT06888921) assessing COM701 as maintenance therapy, with the poster available on Compugen’s website post-congress.
2. MAIA-Ovarian Adaptive Platform Trial Overview
The MAIA-ovarian trial is evaluating safety and efficacy of COM701, a potential first-in-class anti-PVRIG antibody, in relapsed platinum-sensitive ovarian cancer patients without a standard maintenance option. COM701 has shown favorable tolerability and durable responses in heavily pre-treated, platinum-resistant cases, with initial trial data anticipated by Q1 2027.
